GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-03-24| Asia-PacificM&A

Fujifilm’s Cell Culture Branch Acquires Recombinant Protein Maker Shenandoah

by Joy Lin
Share To

Fujifilm Irvine Scientific, a cell culture developer and subsidiary of Fujifilm Corporation, is acquiring Shenandoah Biotechnology, a recombinant protein maker based in Pennsylvania. The production of cell and gene therapies have grown rapidly in recent years, fueled by a hotbed of biopharma interest and investment. 

According to Fujifilm, the acquisition of Shenandoah will provide biopharma customers a one-stop shop for their life sciences research, drug discovery, and cell and gene therapy needs. The Shenandoah deal will also help Fujifilm achieve the sales target of $850 million in their Life Sciences Business by 2025, the company said

 

Profile of Shenandoah

 

Founded in 2006, Shenandoah specializes in mass producing recombinant proteins from E. coli. They mainly focus on manufacturing recombinant cytokines, chemokines, and growth factors for research purposes. That includes PDGF, FGF Basic, and TGF beta 1. 

The biotech recently began producing their line of cell therapy grade products from their GMP facility. Shenandoah also provides custom services ranging from inclusion body protein folding and purification, custom protein expression, and bulk protein production.

The companies did not disclose financial details, but the deal is expected to close later this month. 

 

Fujifilm Irvine Scientific Moves to Expand Cell Culture Media Production

 

Fujifilm Irvine Scientific has been busy expanding its manufacturing capacity for cell culture media, its area of specialty. 

Last December, it established a new innovation and collaboration center in Suzhou New District, China, which will focus on upstream cell culture processes for biomanufacturing. The company the same month announced that its manufacturing plant in the Netherlands (and link to European markets) was fully operational. The Dutch facility adds to Fujifilm’s other plants in the US and Japan, increasing the output of its cell culture media products.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Top 10 U.S. Biomedical & Pharma Clusters of 2024—Part II
2024-08-15
Top 10 U.S. Biomedical & Pharma Clusters of 2024—Part I
2024-08-15
Novo Nordisk’s CLARION-CKD Trial Shut Down After Unsuccessful Results Causing Impairment Loss
2024-07-03
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top